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Introduction
Results from cancer predisposition genetic testing are an 
important component of holistic cancer care and can 
inform treatment, diagnostic, surveillance, and preventative 
health recommendations [1, 2]. Patient experience and 
outcomes of cancer predisposition genetic testing has been 
widely studied, but is largely limited to well- insured, 
Caucasian populations with easy access to genetic coun-
seling and testing services. Information pertaining to 
underserved communities is limited. Underserved com-
munities include individuals with limited financial means, 
and low- socioeconomic status, who may also be racial or 
ethnic minorities and face barriers to genetic testing ser-
vices. Thus, underserved populations remain 
understudied.
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Abstract
Genetic testing for cancer susceptibility has been widely studied and utilized clini-
cally. Access to genetic services in research and practice is largely limited to well- 
insured, Caucasian individuals. In 2009, the Cancer Resource Foundation (CRF) 
implemented the Genetic Information for Treatment Surveillance and Support 
(GIFTSS) program to cover the out- of- pocket expenses associated with cancer 
genetic testing, targeting high- risk individuals with limited financial means and 
limited health insurance coverage. Here, we (i) describe the characteristics of par-
ticipants in the Massachusetts (MA) GIFTSS program and (ii) evaluate mutations 
found in this diverse sample. A secondary retrospective data analysis was performed 
using de- identified demographic data obtained from laboratory requisition forms 
and cancer genetic testing result information from the laboratory source. Eligible 
participants were those who utilized the MA GIFFTS program from 2009 through 
December of 2014. Data were summarized using descriptive measures of central 
tendency. Participants were residents of Massachusetts who had health insurance 
and had a reported income within 250–400% of the federal poverty level. Genetic 
testing results were categorized following clinical guidelines. Overall, 123 (13%) of 
participants tested positive for a mutation in a cancer susceptibility gene. For those 
with a cancer diagnosis, 65 (12%) were found to have a positive result and 20 
(7%) had a variant of uncertain significance (VUS). For those unaffected patients, 
58 (15%) had a positive result and 10 (3%) were found to have a VUS. The 
results from this study are useful in describing genetic testing outcomes in this 
high- risk underserved community. Repeatedly, the literature reports that individuals 
from diverse or limited resource settings are less likely to access genetic testing. 
Continued research efforts should be devoted to promoting the access of genetic 
testing in the high- risk, underserved community.
Cancer Medicine
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Costs of the genetic test and limitations to health insur-
ance coverage are barriers to genetic testing. Cragun et al. 
(2015) identified that having public health insurance, with 
an implied limitation to coverage was a barrier to utiliz-
ing genetic testing in young black women [3]. Low house-
hold income [4], and/or low education [5] are also 
associated with poor uptake of genetic testing, with most 
data coming from BRCA1/2 gene testing. Out- of- pocket 
costs associated with genetic testing even in the insured 
have also been identified as a barrier, regardless of race 
or ethnicity [6]. Including individuals who are cared for 
in the community is a priority at the national level, though 
still equitable representation of diverse individuals has not 
yet been realized [7]. Therefore, data available related to 
outcomes of genetic testing in diverse and unselected 
populations, are often those not included in historical 
clinical research, and is limited.
In 2009, the Cancer Resource Foundation (CRF), a 
501(c)(3) program led by oncology and public health nurse 
leaders, initiated the Genetic Information for Treatment 
Screening and Surveillance (GIFTSS) voucher program in 
Massachusetts (MA) to support the underinsured who 
could not afford the out–of- pocket expenses associated 
with genetic testing. Underinsured individuals were defined 
as those individuals who have health insurance that covers 
some health costs, but whose health insurance neglects to 
cover the entire costs of specific medical tests. This leaves 
these underinsured with either no access to the specific 
test or with a high out- of- pocket cost. At the time of 
inception of the program, the MA Healthcare Reform Act 
(HCRA), which was enacted in 2006, provided compre-
hensive health insurance to adults earning up to 150% of 
the federal poverty level. The MA HCRA did not include 
genetic testing as a covered service. Because individuals 
covered under the HCRA did have health insurance, par-
ticipants in this program were not eligible for local or 
national financial relief programs. Thus, those individuals 
covered under HCRA had neither access to genetic testing 
as a covered benefit through their insurance nor the ability 
to seek outside relief programs.
The eligibility of individuals for the GIFTSS program 
met medical high risk as defined by the National 
Comprehensive Cancer Network (NCCN) [1, 2] if appro-
priate, and the referring clinician verified that the participant 
was appropriate for genetic testing. Referring clinicians 
were typically clinical genetic counselors, OB/GYN provid-
ers, and medical oncologists. Participants also met a financial 
need criterion and were considered eligible if they had a 
household income within or below 250–400% of the federal 
poverty level, and had health insurance that did not cover 
genetic testing. The criteria for financial inclusion was 
broadened from 250 to 400% to meet the needs of not 
only those whose insurance offered no coverage for genetic 
testing but also for those who did have some coverage 
but could not afford the out- of- pocket expenses.
The CRF relied on referring clinical experts (e.g., genetic 
counselors) to identify at- risk individuals who needed 
referral to the GIFTTS resource. The patient and provider 
completed the application for voucher assistance. Once 
completed, the provider ordered genetic testing and CRF 
evaluated eligibility based on financial need. Once an 
application is submitted, a voucher to cover the out- of- 
pocket costs associated with obtaining genetic testing was 
provided. No direct clinical care, genetic counseling, or 
direct (cash) reimbursement to the patient was provided 
as part of GIFTSS, although advanced practice nurses with 
expertise in cancer and genetics were available to facilitate 
answering questions or identifying resources as needed. 
Previous research conducted with a subset of participants 
who took part in GIFTSS had indicated that the program 
included a diverse group of individuals [8]. Data from 
our first study (N = 128) included participants from the 
same cohort and indicated that approximately half of the 
participants had a high school education or less, over 
half utilized state health insurance, and were from over 
31 different ancestral backgrounds [8].
Objectives
The objectives of this analysis were to: (i) describe the 
characteristics of participants from the MA GIFTSS pro-
gram and (ii) evaluate the types of mutations found in 
this sample.
Method
A secondary analysis of data collected from 2009 to 2014 
was completed using de- identified demographic and genetic 
testing results obtained from the laboratory source. Partners 
Healthcare Institutional Review Board reviewed the protocol 
and determined it exempt. All data were summarized using 
descriptive statistics (frequency and proportion). Age at 
the time of genetic testing and cancer diagnosis were 
reported using median and range. Individuals were catego-
rized based on gender, ancestry (as classified by the refer-
ring provider), presence or absence of a cancer diagnosis, 
timing of genetic testing in relation to a cancer diagnosis 
(before a cancer diagnosis/unaffected, at the time of diag-
nosis, or after cancer diagnosis), genetic testing results, 
and presence or absence of a reported family history of 
cancer. Genetic testing results were defined by three cat-
egories [9]: (i) Positive, where a deleterious gene mutation 
or likely deleterious mutation was identified, (ii) Uncertain, 
where a DNA variant of uncertain significance (VUS) or 
favor polymorphism (likely benign), was identified, and 
(iii) Negative, where no mutation was identified.
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Results
Genetic testing results were available for 927 of 928 par-
ticipants who took part in the voucher program. Participant 
characteristics are detailed in Table 1. The median age at 
the time of genetic testing was 46 years (range 3–86 years). 
Ten individuals were tested under the age of 18 (range 
3–17). All minors were tested for mutations in the APC 
gene due to risk for Familial Adenomatous Polyposis, which 
is clinically indicated as standard of care [2, 10].
There were 123 (13%) individuals with gene mutations 
identified that were considered positive.
The family history information of the participants can 
be found in Table 1. For those individuals who had a 
cancer diagnosis, 413 (76%) also reported a first- degree 
relative (FDR) with cancer and for those who did not 
have a cancer diagnosis, 378 (98%) had a FDR with cancer. 
The age at time of first cancer diagnosis was known for 
522 individuals. The median age at diagnosis was 44 years 
(range 16–78 years). The number of individuals with a 
cancer diagnosis who received genetic testing at the same 
time or after their cancer diagnosis was 508 (54%).
Participants underwent a variety of cancer genetic tests, 
including single- site gene testing for known family muta-
tions, multisite gene testing, multi- gene panel, and large 
rearrangement testing. The genes analyzed for the cohort 
included: BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, 
EPCAM, APC, MYH, CDKN2A, CDK4, TP53, PTEN, 
STK11, CDH1, BMPR1A, SMAD4, PALB2, CHEK2, ATM, 
NBN, BARD1, BRIP1, RAD51C, and RAD51D. Table 2 
describes the name of the tests completed, the genes asso-
ciated with that test, and the frequency with which the 
test was used in this sample. Table 3 describes the fre-
quency of genetic tests completed and mutations detected.
The breakdown of mutations by cancer diagnosis is 
described in Table 4. Of those with a cancer diagnosis, 63 
(12%) individuals reported more than one diagnosis of 
cancer. Sixty- five (12%) were found to have a deleterious 
or likely deleterious mutation and 20 (7%) had a VUS. 
For unaffected participants, 10 (3%) were found to have 
a VUS and 58 (15%) had a deleterious/likely deleterious 
mutation and of which 46 (79%) of those were found 
through single- site testing for a known genetic mutation 
within a family. Single- site gene testing (15%) was performed 
on 140 individuals (15%), a positive gene mutation was 
identified in 62 (44%) participants. Of those who underwent 
single- site testing, 108 individuals were unaffected.
Discussion
Here, we report individual- level genetic findings in an at- 
risk cohort of program participants with low- socioeconomic 
status in MA. Our findings demonstrate that genetic testing 
can provide valuable information within this community 
and to reach equitable genetics care, reducing barriers to 
accessing genetic testing should be addressed. The findings 
from this study should be interpreted within the socialeco-
logical context of the multiple systems that impact genetic 
testing uptake, including health system, policy, and 
community- level factors [11]. The unmet need filled by 
this voucher program highlights a gap in the current health 
care systems ability to meet the capacity of a socially and 
economically diverse community.
In our sample of individuals at high risk for having a 
genetic predisposition to cancer who had financial need 
for assistance to obtain genetic testing, 42% of participants 
were unaffected with cancer, and of those who were 
Table 1. Patient characteristic and gene mutation summary for those 
tested.
Participant characteristic N (%)
N 927
Gender
 Female 839 (90)
 Male 78 (8)
 Unknown 10 (1)
Ancestry (may select more than 1)
 African 83 (9)
 Asian 30 (3)
 Central/Eastern Europe 86 (9)
 Latin American/Caribbean 181 (19)
 Native American 39 (4)
 Neareast/Mideast 11 (1)
 Western/Northern Europe 459 (49)
 Unknown 140 (15)
Ashkenazi descent 32 (3)
Timing of genetic testing in relation to cancer diagnosis1
 Before cancer diagnosis (unaffected) 392 (42)
 At same age as cancer diagnosis 227 (24)
 At age after cancer diagnosis 281 (30)
 Unknown 27 (3)
Age at genetic testing, median (range) [n = 913] 46 (3- 86)
Gene mutation2 151 (16)
 Deleterious 118 (13)
 Likely 5 (<1)
 Uncertain 30 (3)
Family history based on presence or absence of cancer diagnosis
With a cancer diagnosis 541 (58)
Family history of cancer 413 (76)3
No family history of cancer 127 (23)3
Not reported 1 (<1)3
Without a cancer diagnosis 386 (42)
Family history of cancer 378 (98)3
No family history of cancer 8 (2)3
1Based on age of genetic testing and age of cancer diagnosis.
2Four individuals had more than 1 mutation; two with a deleterious 
mutation and a VUS (variant of uncertain significance), and two indi-
viduals with 2 VUS.
3Percentage calculated from the number developing or not developing 
cancer.
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unaffected, 98% had a first- degree relative (FDR) with 
cancer. Of those with a cancer diagnosis, the median age 
of onset was young, age 44. Therefore, our findings indi-
cate that referral to GIFTSS was likely highly selective 
and that those individuals were likely appropriately referred, 
though this could not be confirmed. Our cohort’s testing 
included genes other than BRCA1 and BRCA2, a focus 
of most research in diverse groups [12–16], making our 
work novel to the current state of genetic testing in rou-
tine care. A clinically actionable genetic mutation was 
found in 13% of our sample, while 3% had a VUS, which 
is consistent of rates of mutations identified in other 
Table 2. Frequency and type of tests ordered.
Name of test Genes included in test N %
Myrisk BRCA1, BRCA2, MLH1, MSH2, MSH6, PMS2, EPCAM, APC, MYH, CDKN2A, CDK4, TP53, PTEN, STK11, 
CDH1, BMPR1A, SMAD4, PALB2, CHEK2, ATM, NBN, BARD1, BRIP1, RAD51C, RAD51D
18 2
BART BRCA1, BRCA2 352 38
BRCA analysis BRCA1, BRCA2 554 60
Single- site BRCA1 BRCA1 59 6
Single- site BRCA2 BRCA2 49 5
Multisite BRCA1, BRCA2 24 3
APC APC 19 2
Colaris MLH1, MSH2, EPCAM, MSH6, PMS2, APC, MYH 62 7
Colaris AP MLH1, MSH2, EPCAM, MSH6, PMS2, APC, MYH 64 7
PMS2 PMS2 59 6
MLH1 panel MLH1 2 0
MSH2 panel MSH2 3 0
MYH MYH 24 3
EPCAM EPCAM 2 0
Single- site MLH2 MLH1 4 0
Single- site MSH2 MSH2 13 1
Single- site MSH6 MSH6 5 1
Table 3. Number of individuals tested for a gene mutation in each gene and the results of that testing.
Gene tested Associated cancers or cancer syndrome No. tested Result
No. with findings 
N (%)1,2
No. of patients 927 - 151 (16)
Deleterious/likely mutations 123 (13)
APC Familial Adenomatous Polyposis (FAP) 94 APC – Deleterious 6 (6)
MYH MYH- associated polyposis (MAP) 89 Biallelic MYH 1 (1)
Monoallelic MYH 5 (6)
BRCA1 Hereditary Breast and Ovarian Cancer Syndrome 
(HBOC)
745 BRCA1 – Deleterious 50 (7)
BRCA2 HBOC 735 BRCA2 – Deleterious 45 (6)
BRCA2 – Likely 3 (<1)
MLH1 Lynch Syndrome (LS) 118 MLH1 – Deleterious 3 (2)
MSH2 LS 125 MSH2 – Deleterious 6 (5)
MSH2 – Likely 2 (2)
MSH6 LS 117 MSH6 – Deleterious 2 (2)
VUS 30 (3)
APC FAP 94 APC 4 (4)
ATM Breast and pancreatic cancers 18 ATM 1 (6)
MYH MAP 89 MYH 2 (2)
BRCA1 HBOC 745 BRCA1 3 (<1)
BRCA2 HBOC 735 BRCA2 10 (1)
BRIP1 Breast and ovarian cancers 18 BRIP 3 (17)
MSH2 LS 125 MSH2 1 (<1)
MSH6 LS 117 MSH6 5 (4)
PMS2 LS 118 PMS2 3 (2)
1Four individuals had more than 1 mutation; two with a deleterious mutation and a VUS, and two with 2 VUS.
2Percentage calculated from those tested.
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underserved populations [14, 17, 18]. Therefore, in this 
sample, when financial barriers were removed, we see that 
this population had comparable rates of positive genetic 
testing results as reported in the literature.
Single- site testing for a familial mutation was performed 
in 15% of our sample. In this subset of patients, 44% 
tested positive, and were given recommendations for medi-
cal management based on their results. For those 
Table 4. Number of mutations detected based on cancer diagnosis. (Continued)
Table 4. Number of mutations detected based on cancer diagnosis.
Total number of cancer 
diagnoses Mutations identified Number of deleterious Number of likely Number of VUS
Cancer diagnosis
Breast1 400 BRCA- 1 18 – 3
BRCA- 2 21 3 3
BRIP1 – – 1
Ovary 27 BRCA- 1 4 – –
BRCA2 1 – –
Colorectal1 49 APC 1 – –
MLH1 2 – –
MYH – – 1
Mono- MYH 1 – –
MSH2 1 – 1
MSH6 1 – 2
PMS2 – – 1
BRIP1 – – 1
Colon adenomas/polyps 60 APC 2 – 3
MYH – – 2
Bi- MYH 1 – –
Mono- MYH 2 – –
MSH2 2 2 –
MSH6 – – 2
PMS2 – – 2
BRCA2 – – 1
Desmoid tumors 1 – – – –
Jejunum 1 MSH2 1 – –
Pancreas 6 BRCA2 – – 1
Prostate 3 MSH2 – 1 –
Endometrial/uterine 15 Mono- MYH 1 – –
MSH2 – 1 –
Renal pelvis 2 MSH6 1 – –
Fallopian tube 3 BRCA1 1 – –
Cervix 5 MSH2 1 – –
Melanoma 7 MLH1 1 – –
Thyroid 4 – – – –
Bladder 1 – – – –
Leukemia 3 – – – –
Sarcoma 1 BRCA1 1 – –
Sebaceous 3 MSH2 2 – –
Other 21 BRCA1 2 – –
Mono- MYH 1 – –
MSH2 – – 1
No cancer diagnosis 386
APC 4 – 1
ATM – – 1
BRCA1 26 – –
BRCA2 23 – 5
BRIP1 – – 1
MLH1 1 – –
Mono- MYH 2 – –
MSH6 – – 2
MSH2 2 – –
1N = total number of identified mutations and includes individuals with more than 1 mutation; 63 individuals reported more than 1 cancer diagnosis 
(55 reported 2 and 8 reported 3), and therefore the individual participant’s gene mutation may be represented within multiple cancer diagnoses.
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individuals in the subset who did not have a familial 
mutation, the emotional and financial benefit of learning 
of these negative results and not needing additional medi-
cal intervention may be beneficial at both the individual 
and at the larger economic level.
In 2006, MA was the first state to enact the HCRA, 
followed by the National Affordable Care Act (ACA) signed 
into law 3/23/2010 with most provisions taking place on 
January 1, 2014. Although universal healthcare is manda-
tory in the state of MA, it seems clear that the state still 
has a significant population of underinsured individuals 
when it comes to genetic testing services. This study 
included over 900 participants who received services from 
2009 to 2014. Updated data from 2016 indicates that 
over 1600 Massachusetts residents have now received ser-
vices from the GIFTSS program, clearly demonstrating a 
need in our community. The ACA has a provision to 
offer “essential health benefits” for preventive and wellness 
services, guided by the US preventative Services Task Force. 
Genetic testing covered under this act includes testing 
for “BRCA- related Cancer”. These benefits do not extend 
to those with a diagnosis of cancer or more rare cancer 
syndromes.
Additionally, laws surrounding health insurance, specifi-
cally for those with federal insurance, vary from state to 
state and often impact the underserved [6]. Even with 
the ACA in place, certain private and public health plans 
do not cover services such as genetic testing. Some plans 
were grandfathered into the ACA and therefore, not 
required to meet current standards and recommendations 
of the United States Preventative Services Task Force 
(USPSTF) [19]. Government insurance programs have 
limitations on who can be covered for genetic testing 
and when that genetic testing can occur. For example, 
Medicare enrollees unaffected by cancer do not meet cri-
teria for coverage of genetic testing [6]. Both the ACA 
and Medicare policy would have eliminated coverage for 
386 individuals in our sample, 15% who had a clinically 
actionable gene mutation that may have direct relevance 
to cancer treatment and care for at- risk relatives. Therefore, 
without assistance through the GIFTSS program, these 
at- risk individuals and their families could have potentially 
missed the opportunity to know their cancer risk, which 
has individual, family, health care system, and societal 
implications.
Some private insurers place additional restrictions. For 
instance, genetic counseling by an approved genetic coun-
selor is required prior to testing. This may limit access 
in rural or underserved communities where genetic coun-
selors might not be available. Alternative models of pro-
viding cancer genetic counseling might be of benefit to 
at- risk individuals, such as through telegenetic counseling 
or video counseling. In a randomized trial, telegenetic 
counseling has been shown to be noninferior to in- person 
counseling, although it did lead to lower rates of genetic 
testing uptake [20]. Utilizing a novel method of genetic 
counseling might help leverage resources to bring qualified 
professionals into the community. Other research indicates 
that telegenetics is considered convenient by participants 
[21] and more cost effective compared to in- person coun-
seling [22]. Video counseling has also been shown to be 
feasible and acceptable to patients [23, 24]. The importance 
of identifying new ways of providing genetic services to 
communities that serve individuals who are racially, ethni-
cally, or socially diverse is exceedingly important given 
the lack of diversity in the current workforce of genetic 
counselors [25] and low rates of genetic testing referral 
in racial or ethnic minority groups [26]. Therefore, to 
continue to reach underserved communities, genetic coun-
selors and other genetics clinicians should utilize different 
approaches to make genetic counseling convenient and 
accessible.
Furthermore, the results of genetic testing may lead to 
additional treatment, diagnostic, or prevention recom-
mendations. Co- payments and deductibles for those ser-
vices may prove to be prohibitive in pursuing treatment 
recommendations based on the results of the testing [27]. 
The full magnitude of potential that comes from genetic 
testing can only be realized if at- risk individuals, and 
their potentially at- risk relatives, can access lifesaving early 
detection and prevention resources. Future research should 
expand upon this work to further evaluate how at- risk 
individuals within this population are referred for and 
access follow- up care. It remains to be seen if assisting 
high- risk individuals in the MA community to access 
genetic testing can make a positive impact on cancer 
prevention and early detection in this population.
Limitations
Our study has some limitations that should be noted. 
First, the accuracy of information entered on laboratory 
test requisition forms could not be verified. Although the 
test requisition forms ask for patient characteristics includ-
ing family history information, it is unclear as to how 
deliberate these are completed by referring health care 
providers. Second, we were unable to capture additional 
socioeconomic information because this was a secondary 
data analysis. Further, sociodemographic data were limited 
to what was included on the laboratory case report forms. 
Therefore, data such as work status, marital status, and 
other sociodemographic characteristics were not included. 
Finally, we were unable to identify the number of unique 
families included in our sample because data were de- 
identified and specific mutation information was not 
available. It is possible that multiple individuals from the 
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same family may have been included which may inflate 
the mutation rate.
Conclusion
The results from this study are useful in describing genetic 
testing outcomes in this high- risk underserved community. 
Future work is needed to evaluate mutation rates in diverse 
samples to present a more inclusive description of the 
landscape of hereditary cancer risk in the general popula-
tion. Continued research efforts should be devoted to 
promoting access to genetic testing in the high- risk under-
served community.
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